We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , AbbVie Inc. (ABBV - Free Report) , Nike, Inc. (NKE - Free Report) , Uber Technologies, Inc. (UBER - Free Report) and PayPal Holdings, Inc. (PYPL - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Walmart, AbbVie and Nike
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc., AbbVie Inc. and Nike, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Walmart’s shares have outperformed the Zacks Retail - Supermarkets industry over the past year (+21.5% vs. +19.3%). The company has been benefiting from its robust omnichannel operations due to its efforts to enhance store and online experience. Walmart has been particularly gaining from its efforts to boost delivery services.
Increased market share in grocery continued to boost U.S. comp sales in the first quarter of fiscal 2024, wherein the top and bottom lines beat the Zacks Consensus Estimate and grew year over year. Strong comp sales growth globally, expense leverage and e-commerce growth across all units were upsides.
Although Walmart raised its guidance for fiscal 2024, its adjusted earnings per share view suggests a decline from the year-ago period figure. The company is battling cost inflation, which is likely to remain elevated. An adverse product mix has also been a downside for margins.
Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-6.1% vs. +9.7%). There are concerns about long-term sales growth since Humira generics have entered the U.S. market. Increasing competition from newer therapies is hurting Imbruvica’s sales.
Slowing consumer demand due to economic pressure is hurting the aesthetics franchise’s sales. Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. Estimates have declined ahead of Q2 earnings. AbbVie has a positive record of earnings surprises in recent quarters.
However, AbbVie has several new drugs in its portfolio that have the potential to drive the top line to make up for lost Humira revenues. Skyrizi and Rinvoq have established outstanding launch trajectories. It has several candidates that have blockbuster potential.
Shares of Nike have gained +4.2% over the past year against the Zacks Shoes and Retail Apparel industry’s gain of +9.2%. The company’s results benefited from its business strategy, compelling product innovation and digital leadership. The strong results were also supported by continued strength in retail traffic trends within Nike Direct, which has boosted conversion rates.
Its Consumer Direct Acceleration strategy, along with robust performance in its digital and DTC businesses have been key drivers. Backed by solid consumer momentum, a robust product innovation pipeline and a strong inventory, management provided solid outlook for fiscal 2024.
However, shares of Nike have lagged the industry in the past three months owing to dismal fiscal fourth quarter earnings performance. Nike witnessed decline in gross margin owing to higher freight, logistics and input costs, and currency headwinds.
Other noteworthy reports we are featuring today include Uber Technologies, Inc. and PayPal Holdings, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal
For Immediate Release
Chicago, IL – July 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. (WMT - Free Report) , AbbVie Inc. (ABBV - Free Report) , Nike, Inc. (NKE - Free Report) , Uber Technologies, Inc. (UBER - Free Report) and PayPal Holdings, Inc. (PYPL - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Walmart, AbbVie and Nike
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc., AbbVie Inc. and Nike, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Walmart’s shares have outperformed the Zacks Retail - Supermarkets industry over the past year (+21.5% vs. +19.3%). The company has been benefiting from its robust omnichannel operations due to its efforts to enhance store and online experience. Walmart has been particularly gaining from its efforts to boost delivery services.
Increased market share in grocery continued to boost U.S. comp sales in the first quarter of fiscal 2024, wherein the top and bottom lines beat the Zacks Consensus Estimate and grew year over year. Strong comp sales growth globally, expense leverage and e-commerce growth across all units were upsides.
Although Walmart raised its guidance for fiscal 2024, its adjusted earnings per share view suggests a decline from the year-ago period figure. The company is battling cost inflation, which is likely to remain elevated. An adverse product mix has also been a downside for margins.
(You can read the full research report on Walmart here >>>)
Shares of AbbVie have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-6.1% vs. +9.7%). There are concerns about long-term sales growth since Humira generics have entered the U.S. market. Increasing competition from newer therapies is hurting Imbruvica’s sales.
Slowing consumer demand due to economic pressure is hurting the aesthetics franchise’s sales. Nonetheless, though revenues are expected to decline in 2023, AbbVie expects to return to robust sales growth in 2025. Estimates have declined ahead of Q2 earnings. AbbVie has a positive record of earnings surprises in recent quarters.
However, AbbVie has several new drugs in its portfolio that have the potential to drive the top line to make up for lost Humira revenues. Skyrizi and Rinvoq have established outstanding launch trajectories. It has several candidates that have blockbuster potential.
(You can read the full research report on AbbVie here >>>)
Shares of Nike have gained +4.2% over the past year against the Zacks Shoes and Retail Apparel industry’s gain of +9.2%. The company’s results benefited from its business strategy, compelling product innovation and digital leadership. The strong results were also supported by continued strength in retail traffic trends within Nike Direct, which has boosted conversion rates.
Its Consumer Direct Acceleration strategy, along with robust performance in its digital and DTC businesses have been key drivers. Backed by solid consumer momentum, a robust product innovation pipeline and a strong inventory, management provided solid outlook for fiscal 2024.
However, shares of Nike have lagged the industry in the past three months owing to dismal fiscal fourth quarter earnings performance. Nike witnessed decline in gross margin owing to higher freight, logistics and input costs, and currency headwinds.
(You can read the full research report on Nike here >>>)
Other noteworthy reports we are featuring today include Uber Technologies, Inc. and PayPal Holdings, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.